NFE2L2 and cancer: These included known candidate genes that are already being investigated in clinical trials for OSCC or other cancers such as CDK6, PIK3CA, and FGFR1, as well as novel genes that are yet to be explored as therapeutic targets, including those within the oxidative stress pathway (KEAP1, NFE2L2). Notably, we showed that about 5% (45/918) of these genes are highly tractable with approved drugs, or have drugs that are in late-stage of clinical testing, demonstrating that these screens could help to prioritize drugs that could be repurposed for OSCC treatment.